Budweiser Brewing Company APAC Limited (BDWBY) Q1 2026 Earnings Call Transcript
Budweiser Brewing Company APAC Limited (BDWBY) Q1 2026 Earnings Call Transcript
seekingalpha.com
CRNX(CRNX)
CRNX
Earnings in 2 days · May 7, 2026 · After close
Signal
Mixed1↑1↓
PRICE
Prev Close
39.02
Open
39.00
Day Range39.00 – 41.27
39.00
41.27
52W Range25.83 – 57.99
25.83
57.99
48% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-8.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.20
Market-like
Performance
1D
+5.72%5D
+9.91%1M
+9.42%3M↓
-13.03%6M
-2.96%YTD
-11.39%1Y↑
+22.59%Best: 1Y (+22.59%)Worst: 3M (-13.03%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +422% YoY · 108% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 12.3 · FCF negativeBullish
Key MetricsTTM
Market Cap$4.32B
Revenue TTM$5.42M
Net Income TTM-$465.32M
Free Cash Flow-$383.68M
Gross Margin108.5%
Net Margin-8585.2%
Operating Margin-9534.5%
Return on Equity-41.5%
Return on Assets-41.0%
Debt / Equity0.05
Current Ratio12.32
EPS TTM$-4.95
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
2 strong1 watch3 concern
38/100Liquidity
12.32Strong
Leverage
0.05Strong
Coverage
0.0xConcern
ROE
-41.5%Concern
ROIC
-48.9%Concern
Cash
$102MWatch
ANALYST COVERAGE18 analysts
BUY
▲ +110.9%upside to target
L $67.00
Med $87.00consensus
H $105.00Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
✗RSI RangeRSI 48 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 12.32 — healthy liquidity
Upcoming Events
EEarnings ReportMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 107 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ UptrendDeath Cross · 50D trails 200D by 2.5%
+4.6% vs SMA 50 · +2.0% vs SMA 200
Momentum
RSI47.7Neutral territory
MACD+0.76Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$57.99+40.6%
EMA 50
$47.75+15.8%
Current
$41.25
EMA 200
$36.95-10.4%
52W Low
$25.83-37.4%
52-Week RangeMid-range
$25.8348th %ile$57.99
Squeeze SetupVolume-based
Distribution PressureDistribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
20-Day Money Flow
Acc days:4
Dist days:5
Edge:+1 dist
Volume Context
Avg Vol (50D)776K
Recent Vol (5D)
730K-6%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 11 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $6.3M $4.6M–$7.5M | — | -$5.03 | — | ±2% | High11 |
FY2026(current) | $61.8M $57.4M–$66.5M | ▲ +877.3% | -$4.81 | — | ±31% | High11 |
FY2027 | $176.2M $138.0M–$220.9M | ▲ +185.0% | -$4.13 | — | ±31% | High10 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryCRNX
Last 8Q
-4.7%avg beat
Beat 2 of 8 quartersMissed 6↓ Estimates falling-11%
Q2'24
-9%
Q3'24
-5%
Q4'24
+4%
Q1'25
-5%
Q2'25
-9%
Q3'25
-9%
Q4'25
+6%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $3.4M sold · 30d window
Knight Jeff E.Chief Dev. & O…
$3.4M
Apr 8
SELL
Knight Jeff E.COO
$221K
Mar 16
SELL
Knight Jeff E.COO
$150K
Mar 16
SELL
Betz Stephen F.Chief Scientif…
$236K
Mar 16
SELL
Betz Stephen F.Chief Scientif…
$160K
Mar 16
SELL
Struthers Richard S…Dir
$490K
Mar 16
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
Pictet Asset Management Holding SA
1.9M▲2
Candriam S.C.A.
831K—3
abrdn plc
820K▲4
Nuveen, LLC
551K▲5
BRAUN STACEY ASSOCIATES INC
325K▲6
MOODY ALDRICH PARTNERS LLC
183K▲7
ENVESTNET ASSET MANAGEMENT INC
151K▲8
Handelsbanken Fonder AB
30K—News & Activity
CRNX News
20 articles · 4h ago
Intertek surges on third offer from Swedish private equity firm EQT
proactiveinvestors.co.uk
Mastercard Targets the Hidden Cost of Late B2B Payments
pymnts.com
Strauss Group Announces Timing of First Quarter 2026 Earnings Release and Webcast
prnewswire.com
ECCA and TTEC Release “Visionary Voices” Research on the Future of Contact Centre Sales in Europe
globenewswire.com
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
globenewswire.com
Schindler Selects Navan to Elevate Global Travel Operations
businesswire.com
Volkswagen Financial Services Poland marks three years of strong ABS performance with BearingPoint
businesswire.com
European shares slip as US-Iran tensions escalate, oil stays elevated
invezz.com
Stock Market Today: Brent Crude Steadies Near Multiyear High
wsj.com
Oil Price Forecast: Brent and WTI Eye Breakout as Fuel Shortage Risk Grows
fxempire.com
PWB: High Expectations, Compressed Forward Returns, A Fundamental Avoid At Present
seekingalpha.com
Faron Pharmaceuticals Ltd: Holding(S) In Company
accessnewswire.com
Hexagon Purus ASA: Invitation to the presentation of first quarter 2026 results
globenewswire.com
Apple's chip talks with Intel and Samsung signal a structural shift in how Big Tech thinks about supply chain risk
proactiveinvestors.co.uk
Lululemon Stock Investors Might Be Surprised to See This
fool.com
CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise
seekingalpha.com
The Baldwin Insurance Group, Inc. (BWIN) Q1 2026 Earnings Call Transcript
seekingalpha.com
What UniCredit's $28B Commerzbank bid mean for European banking?
invezz.com
Trump Plays Down Iran Attacks on Ships in Hormuz. Oil Prices Tell a Different Story.
barrons.com
About
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
R. Scott Struthers
Website
Robert CuddihySenior Vice President of Medical Affairs
R. Scott StruthersFounder, President, Chief Executive Officer & Director
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CRNX◀ | $41.25 | +5.72% | $4.3B | — | +64071.2% | -604621.9% | 1500 |
| $68.99 | +0.00% | $13.4B | — | — | — | 1500 | |
| $91.17 | +0.00% | $12.0B | — | — | -4239.0% | 1500 | |
| $518.66 | +0.96% | $11.9B | — | — | -3008.0% | 1500 | |
| $223.70 | +8.31% | $11.4B | — | +6554.5% | -2868.8% | 1500 | |
| $76.39 | +0.00% | $10.7B | 52.9 | +2325815.3% | -19.7% | 1500 | |
| $182.03 | +0.00% | $10.6B | — | — | — | 1500 | |
| Sector avg | — | +2.14% | — | 52.9 | +798813.7% | -122951.5% | 1500 |